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Abstract: Ibrutinib is an orally available, small-molecule tyrosine kinase inhibitor. Its main purpose
is to inhibit Bruton’s tyrosine kinase (BTK), an enzyme that is crucial in B cell development.
It is FDA approved for the treatment of certain hematological malignancies. Several promising
off-target drug effects have led to multiple, mostly preclinical investigations regarding its use in
solid tumors. Unfortunately, data on its effectiveness in gynecological malignancies are limited,
and (systematic) reviews are missing. The objective of this review was to summarize the existing
literature and to analyze the evidence of ibrutinib as a treatment option in gynecological malignancies,
including breast cancer. Studies were identified in MEDLINE and EMBASE using a defined search
strategy, and preclinical or clinical research projects investigating ibrutinib in connection with these
malignancies were considered eligible for inclusion. Our findings showed that preclinical studies
generally confirm ibrutinib’s efficacy in cell lines and animal models of ovarian, breast, and endometrial
cancer. Ibrutinib exerts multiple antineoplastic effects, such as on-target BTK inhibition, off-target
kinase inhibition, and immunomodulation by interference with myeloid-derived suppressor cells
(MDSCs), programmed death-ligand 1 (PD-L1), and T cell response. These mechanisms were
elaborated and discussed in the context of the evidence available. Further research is needed in order
to transfer the preclinical results to a broader clinical appliance.
Keywords: ibrutinib; Bruton’s tyrosine kinase; Btk; kinase inhibitor; ovarian cancer; endometrial cancer;
breast cancer; gynecology; gynecologic oncology; solid tumors
1. Introduction
This publication offered a systematic review of ibrutinib’s current use in gynecological malignancies.
The article is structured in three parts. After a conceptual and terminological introduction to the drug
and the diseases, genes, and proteins covered (I); we next reviewed the existing literature on ibrutinib’s
use in gynecological malignancies, including breast cancer (II); Finally, we analyzed the results and
discussed ibrutinib’s multiple mechanisms of action in the context of the literature available (III).
Ibrutinib is an orally available, small-molecule tyrosine kinase inhibitor. Its main purpose is
to inhibit Bruton’s tyrosine kinase (BTK), a crucial enzyme in the B cell antigen receptor signaling
pathway [1–3]. BTK is a member of the TEC-family kinases (TEC, BTK, BMX, ITK, RLK), a group of
non-receptor kinases that modulate intracellular signaling in B- and T-cells and affect cell proliferation,
survival, and differentiation in various cell types [4]. Ibrutinib blocks BTK by forming covalent bonds
with cysteine 481 near the ATP binding pocket of the enzyme, resulting in an irreversible inactivation
and suppression of downstream effectors [2,4]. In this setting, ibrutinib is FDA approved for the
treatment of adult patients with hematological diseases, such as mantle cell lymphoma (MCL), chronic
lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom’s macroglobulinemia
(WM), marginal zone lymphoma (MZL), and chronic graft versus host disease (cGVHD) [5].
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Besides its well-known and approved effectiveness in hematology, ibrutinib shows some promising
off-target potential due to its efficacy on additional binding sites and enzymes, including tyrosine kinases
that conserve the same Cys481 residue, such as the ERBB family (EGFR, ERBB2/HER2, et al.) [2]. This has led
to several, mostly, preclinical publications, investigating its use in solid tumors [4,6–8]. With an increasing
number of research papers addressing this topic, and new kinase inhibitors (such as neratinib) being legally
approved in this field, the effectiveness of ibrutinib in the treatment of gynecological malignancies and
breast cancer seems plausible, although summarized evidence is missing.
Ibrutinib’s toxicity is mainly explained by its inhibition of related kinases. EGFR inhibition may
cause rash and diarrhea. Its more serious unwanted effects include cardiac events (atrial fibrillation,
rarely ventricular arrhythmia) and bleeding, as BTK and TEC modulate platelet aggregation [9–11].
Further and frequently described side effects include digestive and myelosuppressive disorders,
hypertension, edema, fatigue, and infections [4]. The side effects are generally well manageable,
and combinations of ibrutinib with multiple chemotherapeutic agents and monoclonal antibodies
are safe [3,12–14]. The dosage depends on the underlying disease and ranges from 420 mg daily in
CLL/WM to 560 in MCL. In current trials on solid tumors, daily doses from 420 to 840 mg are being
administered [15–17]. Dose reductions are recommended after certain recurrent toxicities ≥ CTCAE 3◦.
The nonspecificity of ibrutinib has led to the development of several second-generation irreversible
BTK inhibitors [18]. Acalabrutinib is FDA approved for adults with MCL, CLL, and SLL [19]. It inherits
a higher sensitivity to BTK, while it has little or no inhibitory effect on other kinases, such as ITK, EGFR,
ERBB2, ERBB4, JAK3, BLK, FGR, HCK, LCK, SRC, and YES1 [20,21]. Further compounds include
zanubrutinib (FDA approved for the treatment of MCL [22]), tirabrutinib, spebrutinib, and evobrutinib.
All of these drugs show a different selectivity profile against off-target enzymes and are mainly
investigated in B cell malignancies or autoimmune diseases [23–25]. While the reduced off-target
activities of these second-generation BTK inhibitors are thought to minimize side effects [9], this might
arguably also minimize their effect on solid malignancies when compared to ibrutinib. As shown
below, many of ibrutinib’s antineoplastic mechanisms in solid tumors rely on its kinase promiscuity
with efficacy on enzymes, such as EGFR and ERBB2. Furthermore, data on the efficacy of these newer
compounds on diseases outside of the hematological spectrum are scarce or missing. Hence, this
review focused on publications investigating ibrutinib.
Ovarian cancer is one of the leading causes of death from gynecological cancers in developed
countries, with a 5-year survival rate of less than 50% after initial diagnosis. First-line therapy includes
a combination of surgical tumor resection and platinum-based chemotherapy [26]. Current guidelines
recommend the subsequent use of maintenance therapy with a poly-ADP-ribose-polymerase (PARP)
inhibitor in a selected group of patients with stage II–IV disease and BRCA1/2 mutations, who are
in complete or partial remission after primary surgery and chemotherapy [26]. Therapy response is
commonly monitored by measuring levels of CA-125, which is also used to detect residual or recurrent
disease, as well as clinical decision-making regarding imaging and second-look procedures [27].
In cases of recurrent disease, a distinction is made between platinum-sensitive and
platinum-resistant recurrence. The classical definition of platinum sensitivity is recurrence after
a platinum-free interval of > 6 months. There has been some recent controversy regarding this
old definition, questioning whether a definition based on the response to platinum would be more
biologically relevant [28,29].
In cases of platinum-sensitive recurrence, a similar approach of cytoreductive surgery followed
by platinum-based chemotherapy is used. Platinum-resistance is typically seen after prolonged use of
platinum-based chemotherapy due to the development of platinum-resistant clones. In this situation,
platinum-free cytotoxic regimens, targeted agents, and/or best supportive care are recommended in
cases of radiological or clinical relapse [30]. In cases with a purely “biochemical relapse” (increasing
CA-125 without radiologic or clinical evidence of the disease), treatment can be delayed until the
occurrence of symptoms [30].
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Breast cancer is the most common cancer in the female population, accounting for almost a third
of all newly diagnosed cancers in women. Despite great advancements in therapy, it remains the
second leading cause of cancer-related deaths in women due to its high incidence [31].
Breast cancer is typically categorized into subtypes, depending on the expression of hormone
receptors (estrogen, progesterone) and of human epidermal growth factor 2 (HER2/ERBB2). The three
major subtypes, namely, hormone-receptor-positive/HER2-negative cancers (70%), HER2-positive
cancers (15–20%), and triple-negative cancers (15%), vary in prognosis but offer distinctive options for
targeted or systemic treatment [32].
Over 90% of patients present with the non-metastatic disease at diagnosis and are treated
with curative intent. This usually consists of a local (surgical tumor resection) and a systemic
therapy according to the molecular subtype, including endocrine treatment, antibodies against HER2,
and chemotherapy, with a trend towards neoadjuvant systemic treatment in recent years. Adjuvant
radiotherapy is usually recommended after breast-conserving surgery [32].
In cases of metastatic disease, treatment is palliative and depends on the subtype.
Therapeutic choices include endocrine treatment and cyclin-dependent kinase inhibitors for
hormone-receptor-positive subtypes, HER2-targeted antibodies, antibody compounds or tyrosine
kinase inhibitors for HER2-positive tumors, and chemotherapy. Radiotherapy can be used for local
disease control. Recently, the availability of immunotherapy targeting PD-1 and PD-L1 has led to
promising effects in HER2+ and triple-negative breast cancer.
2. Results
2.1. Overview
Of the 92 search results, 12 articles were excluded due to the selection criteria or duplication.
After the abstract/full-text assessment, 69 were excluded because they were unrelated to the topic.
Eleven publications were selected as eligible for inclusion. Figure 1 shows the flow diagram for the
identification of relevant studies. In this results section, the evidence available on the efficacy of ibrutinib
in breast cancer and gynecological malignancy, as summarized in Tables 1–3, has been reviewed.
2.2. Review of Identified Studies
2.2.1. Breast Cancer
In 2014, Grabinski and Ewald [33] tested the efficacy of ibrutinib (alone or in combination with
dactolisib, a PI3K/mTOR inhibitor) on ten different subtypes of breast cancer cells in vitro. Cell viability
after treatment with different concentrations of ibrutinib was measured. While ER+ and triple-negative
cell lines were not significantly attenuated after drug treatment, a significant reduction in the viability
of HER2+ cell lines was demonstrated, even with low drug concentrations (half-maximal inhibitory
concentration IC50 in the lower nanomolar range). Specific inhibition of the phosphorylation of the
cancer-related signaling pathway AKT in HER2+ cells was demonstrated and was postulated as the
underlying mechanism of action. The addition of the dual PI3K/mTOR inhibitor dactolisib further
reduced cell viability in a synergistic manner. Moreover, ibrutinib reduced the phosphorylation and
downstream signaling of the EGFR receptors—ErbB1, ErbB2, and ErbB3. In summary, the study
suggested a potential use of ibrutinib in HER2+ breast cancer.
Sagiv-Barfi et al. [34] investigated the synergistic effects of ibrutinib in combination with anti-PD-L1
antibodies on different cell lines, including 4t1-Luc, a triple-negative breast cancer (TNBC) cell line.
As 4T1-cells express low levels of PD-L1 only and no BTK, no single drug showed any effect on
tumor viability in vitro or in 4T1-xenografted mice. However, a reduction in tumor size, fewer lung
metastases, and an increased survival along with the generation of specific antitumor T-cells were
observed with a combined treatment of ibrutinib and anti-PD-L1.
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Given the fact that ibrutinib may have relevant HER2 targeting activity, Chen et al. [2] sought
to address several critical questions regarding its potential clinical use in HER2-overexpressing
breast cancer through growth inhibition experiments, apoptosis assays, xenograft mouse models,
pharmacokinetics/pharmacodynamics, immunohistochemical analysis, Western blot analysis, cell cycle
assay, BTK occupancy assays, and kinase assays. In these experiments, they were able to show that
ibrutinib demonstrated antiproliferative activity against certain solid tumor cell lines, similar to the
previously published patterns of the known EGFR inhibitors—gefitinib and lapatinib. Cell lines that
depend on HER2 for their proliferation were most sensitive. Mechanistically, the compound was
found to inhibit phosphorylation and downstream signaling of HER2 and EGFR in these cell lines at
concentrations in the nanomolar range, mirroring the effect of other HER2 inhibitors. In comparison to
the potency of other ERBB kinase inhibitors, ibrutinib had a higher potency than lapatinib and gefitinib,
albeit lower than afatinib and neratinib.
In a series of xenograft studies with HER2+ cell lines in mice, ibrutinib slowed tumor progress up
to 90% in a dose-dependent manner in certain series. The maximum effect was seen in mice strains
that achieved a higher drug exposure (probably due to differences in bioavailability), as revealed
by pharmacokinetics. As a promising outlook, the calculated AUC (area under the plasma drug
concentration-time curve) for tumor growth inhibition seemed achievable in humans with a standard
560 mg per day dosing.
 
 
Figure 1. Flow diagram for the identification of relevant studies.
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Table 1. Current evidence of the efficacy of ibrutinib in breast cancer.
First Author
[Ref.]
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Legend: q2w: every 2 weeks; BTK: Bruton’s tyrosine kinase; i.v.: intravenously; CTL: cytotoxic T lymphocytes;
DC: dendritic cell; IC50: half maximal inhibitory concentration; MDSC: myeloid-derived suppressor cell; NSCLC:
non-small-cell lung cancer; ORR: overall response rate; TNBC: triple-negative breast cancer.
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Table 2. Current evidence of the efficacy of ibrutinib in gynecological malignancies.
First Author
[Ref.]
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Stiff et al. investigated the effect of ibrutinib on myeloid-derived suppressor cells (MDSCs) [35].
In tumor-bearing hosts, these cells increased in response to factors released by tumors and stromal
cells, and elevated expression subsequently affected immune response and diminishes the efficacy
of immunotherapy. In their work, they were able to document that human and murine MDSCs
expressed BTK. Furthermore, ibrutinib inhibited the formation of human MDSCs in vitro. In the next
experiment, ibrutinib was fed to mice with xenografted triple-negative mammary tumor cells. This led
to a reduction in immune-suppressing MDSCs in the murine spleen and tumor. Lastly, a murine breast
cancer model was used to assess the efficacy of a combined ibrutinib/anti-PD-L1 treatment, resulting in
a significant enhancement of the immunotherapies’ efficacy.
After reporting that an isoform of BTK (BTK-C) protects breast cancer cells from apoptosis in
2013 [36], in 2016, Wang et al. showed that inhibition of BTK by ibrutinib could decrease cancer cell
survival and prevent drug resistance [37]. They found that HER2+ cell lines were more sensitive to
drug treatment than luminal, triple-negative, or even nontumorigenic cell lines in cell growth assays.
The effect of ibrutinib on monolayer and 3D culture was even more potent than that of lapatinib.
As described earlier [33], the phosphorylation of EGFR, HER2, Her3, and ErbB4 was inhibited, resulting
in a blockage of activating downstream pathways. These effects were confirmed in vivo, together with
growth inhibition of the xenografted tumors in mice.
The authors emphasized ibrutinib’s dual effect on two key growth and survival kinases, namely,
BTK and the EGFR family. This might explain its greater impact on HER2+ cells and provide a strong
rationale for its clinical use, especially since a correlation between the expression of HER2 and BTK
was found in human breast cancer tissue.
As the development of new cancer drugs is slow and costly, Di et al. [38] generated a
novel computational approach in order to determine candidate drugs that could possibly be
repurposed to treat cancer. By using known drug-indication correlations and combining them
with drug-drug and indication-indication similarities, they were subsequently able to hypothesize new
drug-indication associations.
The software used raw data from the National Cancer Institute (NCI)-60 cancer cell line database,
a panel containing extensive data on the gene expression profiles and pharmacology for 60 cancer
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cell lines, including breast and ovarian cancer. These data were used to study the correlation
between mRNA/microRNA expression levels and drug susceptibility. They created a drug-drug
functional similarity network in order to predict drug functional similarities at a biological pathway
level. The system was validated using cross-validation tests on approved drugs, receiver-operating
characteristic curve analysis, and literature searches, confirming its efficiency in prioritizing candidate
cancer drugs.
Sixteen FDA approved drugs for the treatment of breast cancer were mapped to the described
network. The algorithm then identified 14 candidate drugs that were statistically significant. In this list
of prioritized scores, ibrutinib ranked 3rd out of more than 3000 substances tested and was “considered
to show great potential therapeutic effects” [38]. Moreover, ranks 1 and 2 (gefitinib and afatinib)
represented two EGFR inhibitors, additional proof of the importance of this receptor in breast cancer
treatment. After Sagiv-Barfi et al. showed a preclinical effect of ibrutinib and anti-PD-L1 antibodies
in lymphoma, breast cancer, and colon cancer [34], Hong et al. initiated an open-label, multicenter,
phase Ib/II study evaluating ibrutinib plus durvalumab in humans [39]. Inclusion criteria included
patients with stage III/IV breast cancer, pancreatic adenocarcinoma, and non-small-cell lung cancer
(NSCLC). After defining a recommended phase 2 dose of 560 mg ibrutinib p.o. daily and durvalumab
10 mg/kg intravenously (i.v.) twice a week in phase 1, they continued to treat 122 patients at that
dose. Of these patients, 45 had breast cancer (28 TNBC, 17 HER2+), and all of them had previously
been treated with ≥ 2 prior therapies. Ninety-four percent of the patients had stage IV disease at a
median age of 61 years. An overall response rate of 3% was found in patients with breast cancer, with
a median progression-free survival rate of 1.7 months. Pancreatic cancer and NSCLC ranged at an
overall response rate of 2% and 0%, with a median progression-free survival rate of 1.7 and 2.0 months,
respectively. While the safety profiles of both drugs were consistent with previously known data
and were considered acceptable, the antitumor activity in this pretreated, late-stage study population
was limited.
Varikuti et al. [40] used an orthotopic mouse breast cancer model to investigate ibrutinib’s effect
on tumor progression and metastasis. Mice were injected with tumor cells resembling a luminal b
subtype [41]. After a growth period of one week, mice were randomized to treatment or placebo
groups. Tumor progression, as well as tumor weight, were significantly reduced in the treatment
group. BTK expression in tumor tissue was decreased in a dose-dependent manner. Mice receiving
the verum also had fewer lung metastases and splenomegaly when compared to the placebo group.
Immunosuppressive monocytic MDSCs were found to be reduced in the tumors and spleens of
treated mice with an increase in mature dendritic cells (DCs). Furthermore, ibrutinib initiated a
phenotype switch from MDSCs to DCs in vitro. Regarding immune response, the team was able to
show that ibrutinib increased T cell effector functions, encouraged T cell proliferation, and promoted
Th1-dominant cytokines in vivo.
Table 1 shows a summary of the studies described.
2.2.2. Gynecological Malignancies
Zucha et al. [42] studied BTK and its inhibition by ibrutinib comprehensively in human ovarian
cancer tissue samples. They demonstrated a high expression of BTK in malignant cells with more
intense staining in metastatic and late-stage disease.
A further experiment demonstrated that cell lines highly resistant to platinum expressed higher
levels of cancer stem cell (CSC) markers than cells with moderate or absent platinum resistance,
indicating a higher fraction of CSCs in these cells.
Next, spheroids from the parental cell lines were generated, and the cisplatin responsiveness
of spheroids and parental cell lines were compared. Spheroids of CSC-rich cell lines showed high
resistance to platinum, indicating a major role of CSCs in cisplatin resistance, while BTK was critical in
regulating ovarian CSCs.
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To prove the hypothesis that BTK mediates platinum resistance via regulation of CSCs,
loss-of-function and gain-of-function studies were performed. In a primarily platinum-responsive cell
line, the overexpression of BTK stimulated the activation of transcription factor STAT3. Consequently,
several downstream effectors, known for their role in stem cell regulation and cell survival, such as SOX2
and Bcl-xL, were upregulated. Following this “stemness” gene regulation, these cells formed spheroids
and increased their CSC count. In contrast, JAK2/STAT3 targets (such as Bcl-xL) were downregulated in
BTK knockdown loss-of-function studies. Treatment with ibrutinib showed a similar effect, decreasing
BTK phosphorylation and Sox2/Bcl-xL expression. This diminished the self-renewal capacities of
highly malignant cells and their proportion of CSCs, which ultimately reduced the population and its
spheroid-forming abilities. Cell lines initially highly resistant to cisplatin became more sensitive after
BTK knockdown. A synergistic effect of ibrutinib and cisplatin was shown in serous and clear cell
lines, indicating the possible use of ibrutinib as a platinum sensitizer in these malignancies.
There also is evidence for an antiproliferative role of ibrutinib in endometrial cancer.
Tamura et al. [43] created patient-derived tumor organoids (PDOs) from human tumor tissue (lung,
ovarian, endometrial). The morphology, histology, and gene expression of these organoids were
similar to their source tumor. The reaction to a total of 61 anticancer agents was tested in cell growth
inhibition experiments. Subsequently, the efficacy of each anticancer agent was evaluated. A PDO
called REME9 was derived from carboplatin/paclitaxel-resistant endometrial cancer. As expected,
carboplatin and paclitaxel showed only weak effects on this cell line, an observation that suggested
certain comparability between the PDOs and the source tumor regarding the drug response. Ibrutinib
led to growth inhibition in these cells at concentrations (AUC) notably lower than carboplatin and
paclitaxel, but also lower than MTX and vinca alkaloids—substances that current guidelines recommend
as a possible treatment for metastatic patients. However, ibrutinib had much less effect in clear-cell
adenocarcinoma specimens. A comparison with the effect of anthracyclines was not possible, as this
substance class was not investigated.
The drug-drug functional similarity network created by Di et al. [38] has been described in detail
in in Section 2.2.1 above. Even though ibrutinib achieved a high score as a potential agent for breast
cancer treatment, it failed to thrive in the experiments on ovarian cancer and ranged in the last sextile
of the candidate drug list ranking.
As treatment options in platinum-resistant ovarian cancer are scarce, Lohse et al. [44] investigated
the treatment response to 30 FDA-approved chemotherapeutics in six such patient-derived cell lines,
using ex vivo drug sensitivity testing. The experiments were performed on two endometrioid, two
clear-cell, and two papillary-serous cell lines, respectively. To interpret and compare the different
drugs, the modified drug sensitivity score was used, a marker incorporating different parameters, such
as potency, efficacy, effect range, and therapeutic index, allowing for prioritization of compounds with
one sole numerical metric. In light of this personalized medicine approach, differing treatment responses
between cell lines were observed. While docetaxel and cephalomannine diminished the survival of
all cell lines tested, the effect of ibrutinib varied greatly. A weak inhibitory effect was found on one
endometrioid and papillary-serous cell line, respectively, while no effect was seen on clear-cell cancer
lines. Ibrutinib generally provoked less treatment response compared to the tested antimitotics, such
as docetaxel. The response to each drug varied greatly and was partly unpredictable between the
cell lines tested. Afatinib, for example, another kinase inhibitor tested, was the top candidate against
papillary-serous cell line P5X but showed the poorest specificity against the second papillary-serous
cell line P9A1.
Table 2 shows a summary of the studies investigating ibrutinib in gynecological malignancies.
2.3. Clinical Trials
Three trials investigating ibrutinib’s use in gynecological malignancies were identified. Figure A1
(Appendix A) shows the flow diagram for the identification of relevant trials.
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NCT02403271 is a phase Ib/II trial, assessing the safety and efficacy of a combination of ibrutinib
(560 mg daily) and durvalumab in patients with relapsed or refractory solid tumors. As the results have
already been published by Hong et al. [39], please refer to the “Results” section above for further details.
NCT03379428, “Trial of Ibrutinib Plus Trastuzumab in Her2-Amplified Metastatic Breast Cancer”,
is a phase I/II, open-label, nonrandomized dose-escalation study. Its primary objectives are to define a
maximum tolerated dose of oral ibrutinib (420, 560 or 840 mg, phase I) and to assess the clinical benefit
rate (phase II) in patients with HER2+ metastatic breast cancer. At the same time, the patients receive
3-weekly trastuzumab intravenously. With the rationale of continuing a dual HER2 blockade after
the failure of second-line therapy, the inclusion is limited to patients with disease progression after
prior T-DM1. As of May 2020, the trial is active and recruiting, with estimated primary completion in
December 2020.
NCT03525925, “Ibrutinib and Nivolumab in Treating Participants with Metastatic Solid Tumors”,
is a phase I trial investigating the effect of ibrutinib and nivolumab on myeloid-derived suppressor
cells. Patients with metastatic solid neoplasms and any number of prior lines of therapy are eligible
for inclusion. Patients receive oral ibrutinib (420 mg daily) for 15 days and intravenous nivolumab
on days 8 and 21 with subsequent repeated courses of nivolumab every 28 days until disease
progression or unaccepted toxicity. The primary objective is to evaluate the levels of circulating
MDSCs, with a secondary objective being the assessment of the safety of the study combination.
The immunosuppressive potency of MDSCs is measured by their T cell inhibition ability and by
examining antibody-dependent cell toxicity mediated by natural killer cells. The study is active but
not recruiting, with estimated primary completion in September 2020.
In Table 3, we summarized the clinical trials described.
Table 3. Clinical trials investigating the use of ibrutinib in gynecological malignancies, including
breast cancer.
Ref. Title Phase/ Status Brief Summary Primary Outcomes
NCT02403271 [15]




With Relapsed or Refractory
Solid Tumors
Phase Ib/II;
completed 1 (Ref.: Results section,
Hong et al., 2019 [41])
A phase 1b/2, multi-center
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and efficacy of ibrutinib in
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durvalumab (MEDI4736) in






rate per RECIST 1.1
NCT03379428 [16]







study to evaluate the
maximum-tolerated dose
and dose-limiting side
















active, not recruiting 1
A phase I trial investigating
the effect of ibrutinib and
nivolumab on circulating
levels of MDSCs in patients
with metastatic solid tumors





1 Recruiting status as of May 1st, 2020.
3. Discussion
Ibrutinib has surpassed its initial indication for hematological malignancies and is about to acquire
an increasing raison d’être in gynecological malignancies and breast cancer. It has become clear that the
mode of action extends beyond B cells, as the compound affects signaling pathways downstream of
multiple other receptors [4,8]. Its promising efficacy on solid tumors can be explained by different
means. As different tumor types rely on heterogeneous intracellular pathways and greatly vary in
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driver mutations, gene expression, and protein endowment, it is important to note that ibrutinib’s
modus operandi in one tumor cannot be transferred to another. The mechanisms described below consist
of complex interactions between the drug, the tumor, and its microenvironment.
First, ibrutinib shows on-target BTK inhibition in certain solid tumors. Ovarian cancer cells
were found to express BTK, correlating with higher clinical disease stage, the risk for metastasis,
and survival [42]. This could be used as both a prognostic predictor and a pharmacological target.
Furthermore, Zucha et al. showed that ibrutinib diminished the self-renewal capacities and the
proportion of CSCs in ovarian cancer due to their BTK dependence. Cisplatin resistance of CSCs
was surmounted, promoting a synergistic effect of both drugs [42]. While the calculations performed
by Di et al. implied no use as an ovarian cancer drug candidate [21], their results were purely
computational and were never confirmed by testing. In vitro testing performed by Lohse et al.,
however, did show a weak effect on certain cell lines. Further on-target effects were identified by
Eifert et al. [36] and Wang et al. [37]. BTK-C, an isoform of BTK, was expressed in 30% of breast cancer
tissue, with an even higher percentage (43%) in HER2+ tumors. The observed reduction of HER2+ cell
viability is proposed to be mediated via BTK’s role in the AKT-ERK axis. A synergistic effect between
direct inhibition of BTK (-C) and HER2 (as described below) is likely.
Second, the effects of ibrutinib in- and outside the TEC family kinases, which are linked to the
inhibition of certain additional proteins, do exist. In BTK, ibrutinib covalently binds to a cysteine
residue in the ATP-binding domain. Several other enzymes contain homologous cysteine residues at
analogous positions, as it is conserved among at least nine other tyrosine kinases [2]. An effect has been
described for ERBB family kinases (EGFR, HER2, HER3, HER4), TEC family kinases (TEC, BTK, BMX,
ITK, RLK), and others (JAK3, BLK, FGR, HCK, LCK, Yes/YES1) [8,45]. Even at low concentrations of 1
µmol/L, ibrutinib is able to inhibit 16 kinases by > 95% [46].
Changes in the expression or structure of tyrosine kinase receptors are known to be common in
different human cancers and allow for pharmaceutical targeting. Ibrutinib rapidly binds to these targets,
leading to reduced phosphorylation of kinases, such as ErbB1-3 [33]. This inhibition is irreversible,
allowing for its typical once to twice daily dosage despite a short plasma half-life [2].
The inhibitory effect on EGFR has been specifically explored and is effective in different tumor cell
lines, such as EGFR-mutant non-small-cell lung cancer (NSCLC) in mice [7]. Screening of large panels
of cell lines has proved that ibrutinib suppresses the growth of cells suppressed by other EGFR/HER2
inhibitors [2]. Chen et al. did not find an effect of ibrutinib on HER2-negative cell lines during several
broad screenings [2], a finding that strengthens the hypothesis of ERBB family blocking as a main
mode of action.
The effect on the ERBB family, and especially HER2, becomes even more relevant as HER2
overexpression occurs in approximately 20% of breast cancers, resulting in more aggressive subtypes.
In mice xenografted with HER2+ cells, a significant tumor growth inhibition was seen at nanomolar,
clinically achievable concentrations, and is an encouraging result [2,33].
While antibodies targeting HER2 have made their way into everyday clinical practice since long,
experiments in breast cancer cell lines have revealed ibrutinib to be a promising small-molecule
addition to the arsenal. As it is most potent in HER2-overexpressing cell lines, these seem to be among
the most promising candidates for possible future ibrutinib treatment, especially when considering the
synergies described further above. This emphasizes the drug’s multifunctional ability to exert different
antineoplastic mechanisms, as outlined earlier. Combining these multiple effects with additional
pharmaceutical drugs, such as trastuzumab, is an auspicious approach and is currently being explored
in a clinical trial [16]. Ibrutinib’s inhibition of bone marrow X-linked kinase (BMX) is another promising
target but remains largely unexplored in gynecological tumors and breast cancer. BMX is overexpressed
in several tumor types and promotes cell proliferation through the PI3K/AKT pathway. Its blockage
could be of interest, especially when combined with PI3K/AKT inhibitors [4]. It has been shown to be
up-regulated in breast and cervical cancer, enhancing cell proliferation, invasiveness, and migration.
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BMX expression correlates with tumor differentiation and TNM stage [47,48] and is able to increase
apoptotic resistance to chemotherapeutic drugs [49].
Third, immunomodulation relating to MDSC’s and PD-(L)1 seems to play a key role when using
ibrutinib alone or in combination with other therapeutics. MDSCs, which are present in the stroma
of many different tumors, have been shown to cause evasion of antitumor immune responses by
immunosuppression and to reduce the efficacy of immune therapy [3,8]. As they express BTK [35],
the corresponding inhibitors may reduce MDSCs in vivo. Additionally, ibrutinib diminishes cytokine
production, PD-L1 expression, and motility of MDSCs and other myeloid cells, which consequently
affects tumor microenvironment regulation and has been linked to decreased tumor vasculature
density [4]. In the murine model of Stiff et al., treatment with ibrutinib resulted in a reduced frequency
of MDSCs in mammary tumors and significantly improved the efficacy of anti-PD-L1 therapy in breast
cancer, possibly providing a novel strategy for enhancing immune therapies in solid malignancies [35].
Ibrutinib’s influence on circulating MDSCs and its synergistic effect with anti-PD1 targeted therapy are
currently under investigation in humans. We highly anticipate the results of NCT03525925 [17] in order
to improve our knowledge about the effects of this promising combination. The observed synergy
of ibrutinib and immune checkpoint inhibition is in line with the work of Sagiv-Barfi et al., where
the combination of ibrutinib with anti-PD-L1 agents proved efficient even in tumors (lymphomas)
intrinsically insensitive to ibrutinib, with an approx. 50% cure rate in mice. In their breast cancer model,
a similar effect was found despite BTK negativity and low PD-L1 expression. Hypothesizing that the
synergistic effect of ibrutinib augments the effectiveness of the PD1/PD-L1 blockade by increasing
antitumor T cell response [3], these data suggest a novel role of the compound as a booster of T cell
therapies. An increase of CD4+ Th1/Th2 cells and tumor-specific antigen expression by CD8+ T cells
has been outlined on a molecular basis [4], as elaborated in the next paragraph.
Fourth, antineoplastic effects can be explained by further modulation of adaptive immunity.
One mechanism of tumor immune escape is to induce a Th2-dominant helper T cell response with
antibody production instead of a Th1-dominant response. However, ibrutinib causes a shift towards the
favorable Th1-based immune response and cell-mediated cytotoxicity [45,50,51], leading to increased
maturation of cytotoxic T cells and depletion of immunosuppressive cytokines, such as IL-10 and
TGF-β [3]. This effect is mediated by inhibiting interleukin-2-inducible T cell kinase (ITK), a TEC
kinase that modulates the development and function of T cell immune response [34,45], whereas Th1
and CD8+ cells can rely on an escape route for maturation [4].
Ibrutinib’s performance varied greatly between animal and human studies in the trials
described [39,40]. These contrasting results are multicausal. As with every experimental model,
it is challenging to transfer the results to humans, adding numerous layers of complexity to a cell
line or animal model. Even highly promising preclinical results had to be abandoned upon failing to
show results in human trials. Nevertheless, the proposed mechanisms of action have been studied
in-depth and sound plausible. The limited data available on human use are insufficient to render a
complete picture of the drug’s capabilities, even more so, as the study population in the phase 1b/2
trial is heavily pretreated and suffers end-stage disease, which inevitably leads to short life expectancy
and high drop-out quotas. In future research, clear inclusion criteria, ex vivo sensitivity, and genetic
testing will be crucial in order to select prime candidates. With the optimal patient selection, we are
optimistic that the encouraging preclinical results can be transferred to a broader clinical appliance.
As the paradigm in oncology has shifted from mere inhibition of cell division to a more
holistic approach investigating the tumor and its environment, ibrutinib, with its inhibitory and
immunomodulating effects, takes up an intriguing role. Future research should clearly focus on its use
in HER2+ tumors as well as its possibilities as an enhancer of chemo- and immune therapy. In the near
future, the results of the ongoing trials NCT03379428 and NCT03525925 could add further evidence in
respect thereof.
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4. Materials and Methods
4.1. Inclusion Criteria
For this review, studies were considered eligible if they covered (at least in one aspect) the
investigation or use of ibrutinib in gynecological malignancies (including breast cancer) in theoretical
or empirical (human, animal, or in vitro) studies. As per protocol, fundamental research, preclinical,
and clinical studies in English published until April 1, 2020, were considered for this review. We did
not include reviews, conference abstracts, or notes without an abstract. No other restrictions were used.
Clinical trials were considered eligible if they investigated the use of ibrutinib in female genital
tract tumors or breast neoplasms with no further restrictions.
4.2. Search Strategy
We performed electronic database searches in EMBASE (DataStar Version, Cary, NC, USA) and
MEDLINE (Ovid version, New York, NY, USA). The search was conducted using the following
Emtree/MeSH terms: “ibrutinib” or “PCI32765” in combination with “female genital tract tumor”
(Emtree) or “genital neoplasms, female” (MeSH), and “breast tumor” (Emtree) or “breast neoplasms”
(MeSH). The Emtree/Mesh terms were expanded in order to include narrower terms (e.g., “ovary
tumor” or “breast cancer”). Boolean operators were used as conjunctions to extend or limit the search,
as described in Tables A1 and A2. All matching publications were screened. The manual exclusion was
performed after screening the titles and/or abstracts to identify eligible publications. The bibliographies
of all articles that fulfilled the inclusion criteria were reviewed to identify other articles that fulfilled
the inclusion criteria.
Clinical trials were searched in Clinicaltrials.gov (United States Library of Medicine, Bethesda,
MD, USA) using the following terms in the respective search fields condition or disease: “solid tumor”,
“gynecologic cancer”, “ovarian cancer”, “fallopian tube cancer”, “peritoneal cancer”, “cervical cancer”,
“uterine cancer”, “corpus uteri cancer”, “corpus uteri carcinoma”, “endometrial cancer”, “vaginal
cancer”, “vulvar cancer”, “breast cancer”; other terms (medication): “ibrutinib”.
4.3. Data Collection Process, Data Items
Due to inevitable methodological inconsistencies in the studies retrieved and experiments
conducted, standardized data extraction could not be performed. Findings were extracted
independently in a narrative way to the best of our ability.
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Abbreviations
BMX Bone marrow X-linked kinase
BTK Bruton’s tyrosine kinase
cGVHD Chronic graft versus host disease
CLL Chronic lymphocytic leukemia
CSC Cancer stem cell
CTL Cytotoxic T lymphocytes
DC Dendritic cell
EGFR Epidermal growth factor receptor
ER Estrogene receptor
i.v. Intravenously
IC50 Half-maximal inhibitory concentration
IFN Interferon
IL Interleukin
ITK interleukin-2-inducible T-cell kinase
MDSC Myeloid-derived suppressor cell
MeSH Medical Subject Headings
MZL Marginal zone lymphoma
NCI National cancer institute
NSCLC Non-small-cell lung cancer
ORR Overall response rate
PARP poly-ADP-ribose-polymerase
PD-1 Programmed cell death protein 1
PD-L1 Programmed death-ligand 1
PR Progesterone receptor
q2w 2-weekly, every 2 weeks
RLK Redundant-resting lymphocyte kinase
SLL Small lymphocytic lymphoma
TEC Tec protein tyrosine kinase
TFK TEC family kinase
TNBC Triple-negative breast cancer
WM Waldenstrom’s macroglobulinemia
Appendix A
Table A1. Search outcomes in Medline. A search performed on 1 April 2020.
Number Search Terms Search Items Medline
1 ibrutinib (Mesh) 2026 results
2
(‘genital neoplasms, female’ [Mesh]) OR ‘breast neoplasms’
[Mesh]
498.349 results
3 1 AND 2 4 results
Table A2. Search outcomes in Embase. A search performed on 1 April 2020.
Number Search Terms Search Items Embase
1 ibrutinib (Emtree) 6186 results
2 ‘female genital tract tumor’/exp OR ‘breast tumor/exp’ 866.090 results
3 1 AND 2 84 results









Figure A1. Search results of clinical trials.
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